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Abstract: Antioxidants are helpful in prevention of several diseases related with oxidative stress including neurodegenerative disorders. In 
recent studies, carbazoles were given proof of promising antioxidant activities. In this article, 9-ethyl-9H-carbazole hydrazone derivatives were 
synthesized, characterized and their in vitro antioxidant activity and possible cytotoxic effects were investigated. Furthermore, protective effect 
of the synthesized derivatives against amyloid β-induced damage in PC12 neuronal cells was examined by using MTT assay. The newly synthe-
sized carbazoles were found to have radical scavenging activity with a varying potency both in cell-free and cell-based in vitro assays. Several 
compounds, especially such as 3d and 3e, 3m and 3n bearing two halogen groups on the phenyl ring, were found to have cytotoxic activity. 
However, their cytotoxic activities were not higher than that of melatonin. Several compounds also significantly protected neuronal PC12 cells 
against amyloid β-induced damage, which can be defined as neuroprotective agents. (4-(2-((9-Ethyl-9H-carbazol-3-yl)methylene)-
hydrazinyl)benzonitrile) 3r was found as the most active compound with both radical scavenging activity and neuroprotective effects against 
amyloid β-induced damage. These findings might provide an alternative strategy for developing novel carbazole derivatives for management 
of neurodegenerative diseases, such as Alzheimer's disease. 
 





ARBAZOLES represent a family of tricyclic compounds 
which are widely found in nature. Several studies have 
been conducted to reveal biological effects of these com-
pounds since last decade. Therefore, synthesis of substi-
tuted carbazoles have attracted considerable attention.[1] 
Carbazole derivatives have been reported to demonstrate 
diverse biological activities such as antimicrobial, anti-
tumor, antiepileptic, antihistaminic, antioxidative, anti-in-
flammatory, analgesic, neuroprotective and pancreatic 
lipase inhibition properties.[2] Carbazole structure is already 
present in many drugs such as carvedilol,[3] an 
antihypertensive; carprofen,[4] a non-steroidal anti-inflam-
matory agent, carazostatin,[5] an antioxidant (Figure 1).  
N-substituted carbazoles have been also well known for 
their variety of pharmacological activities, such as 
antioxidant[6] and antitumor[7] properties. C  
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 Antioxidant effects of carbazole derivatives are spe-
cially focused in many studies. Thus, 1,3-dihydroxy-2-car-
boxycarbazole analogues exhibited antioxidative proper-
ties, promising neuroprotective activities in a cellular 
model of Alzheimer's disease (AD) and inhibitory activity 
against Aβ aggregation.[8] In another study 1- and 3-substi-
tuted carbazole derivatives were observed with significant 
neuroprotective effects on neuronal cells HT22 against cell 
injury. Substituents introduced to the carbazole ring sys-
tem play crucial roles in their biological activities. It was 
found that bulky groups favour the neuroprotective activ-
ity.[9] 3-Oxygenated and 3,4-dioxygenated carbazole 
alkaloids and their related carbazoles such as  
3,8-dihydroxycarbazoles carbazomadurin A and B showed 
higher antioxidant activities.[10] Bandgar et al.[11] examined 
radical scavenging activity, cytotoxicity and antimicrobial 
activities of novel carbazole chalcones (Figure 2). Most of 
the compounds showed good 2,2-diphenyl-1-picrylhydrazyl 
(DPPH) and hydroxyl radical scavengers activity. 
 A series of carbazole-based sulfonamide and carba-
mate derivatives exhibited antioxidant activities from mod-
erate to good levels. According to the results, the most 
potent antioxidant activities were observed in the com-
pounds having strong electron withdrawing groups such as 
NO2, CCl3, and Cl. This might be related with their high an-
tioxidant activity.[12] Similar to this example, we have deter-
mined that combination of two different pharmacophores 
carbazole and hydrazine derivatives led to series of new 
compounds having antioxidant activity. Similar to carba-
zoles, hydrazone derivatives were also reported to possess 
various pharmacological activities including antioxidant 
activity.[13,14] 
 Many in vitro, in vivo and epidemiological studies 
suggested involvement of oxidative damage in neuro-
degenerative diseases such as Parkinson’s and Alzheimer 
Diseases[15] Elevated DNA oxidation products (such as 8-
OHdG and other DNA base oxidation products), protein ox-
idation products (such as protein carbonyls and nitrotyro-
sine) and lipid peroxidation products (such as 4-HNE) in the 
brain of animals (in vivo studies) suggested as evidences for 
the role of oxidative damage in Alzheimer Diseases.[16,17] 
Therefore, antioxidants seem to be beneficial in prevention 
and/or treatment of Alzheimer Disease. 
 Due to the plaque formation caused by cytosolic 
accumulation of amyloid β-peptide (Aβ), many studies 
have focused on designing new molecules that are able to 
inhibit Aβ aggregation. Saturnino et al.[18] found out two 
promising N-alkyl carbazole derivatives by docking 
simulations which also exhibited the higher activity in 
vitro. N-substituted carbazoles have been reported as 
neuroprotective agents with potent anti-oxidative activity 
performing good neuroprotective effects on neuronal 
cells HT22 against cell injury induced by glutamate or 
homocysteic acid.[9] 
 In the light of these observations, it was taken an 
interest in synthesizing a new class of carbazole-hydra-
zones in order to study the possible antioxidant activity 
and protection of neuronal PC12 cells against amyloid β-
induced damage. Herein, we report the synthesis of 9-
ethyl-9H-carbazole hydrazone derivatives starting from 9-
ethyl-9H-carbazol-3-carboxaldehide and phenyl hydra-
zine derivatives. Their potential antioxidant activity was 
investigated by evaluating their reducing effect against 
oxidation of a redox sensitive fluorescent probe, 2′,7′-
dichlorofluorescin diacetate (DCFH-DA), in a cell-based in 
vitro model and their radical scavenging activity was 
assessed via the 2,2-diphenyl-1-picrylhydrazyl (DPPH) 
assay in a cell-free in vitro model. MTT (3-(4,5-dimethyl-
thiazolyl-2)-2,5-diphenyltetrazolium bromide) assay was 
performed to evaluate cytotoxic activity of the 
compounds and neuroprotective effect was examined in 
PC12. All the analogue compounds were characterized on 




The chemical reagents used in synthesis were purchased 
from Sigma (Germany) and Aldrich (USA). Uncorrected 
melting points were determined with a Buchi SMP-20 
apparatus. The 1H and 13C NMR spectra were measured 
with a Varian 400 MHz using TMS internal standard and 
DMSO-d6 as solvent. ESI Mass spectra were determined on 
a Waters micromass ZQ. FT-IR spectra were recorded on 
Jasco 420 Fourier. Elemental analyses were performed us-
ing CHNS-932 (LECO). All spectral analyses were performed 
at Ankara University Faculty of Pharmacy Central Labora-
tory.  
 RPMI 1640 was obtained from Atocel (Austria). 
Amyloid-β peptide (residues 25 to 35, Aβ25–35) was purchased 
from Tocris Bioscience (USA). Penicillin / streptomycin, 
sterile phosphate-buffered saline (PBS), and trypsin EDTA 
0.25 % were purchased from Shell Max. Fetal bovine serum 
and horse serum were acquired from Thermo Scientific 














Figure 2. General formula of (a) Antioxidant 3-(substituted)-
aryl-5-(9-methyl-3-carbazole)-1H-2-pyrazolines and (b) 
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For the synthesis of new carbazole imine compounds (3a–
3r), phenyl hydrazine derivatives and 9-ethyl-9H-carbazole-
3-carboxaldehyde were heated in the presence of ethanol. 
All the compounds were characterized on the basis of 
spectral data. The characterization results of the novel 
compounds 3e and 3m–r are given as follows. Compounds 
3a–d and 3f–l were previously described by Aboul-Enein.[24] 
General Procedure for the Synthesis of 
Compounds 
9-Ethyl-9H-carbazole-3-carboxaldehyde (0.1 mmol) was 
reacted with phenyl hydrazine or its derivatives (0.13 mmol) 
in 20 mL of EtOH for 3 h on the hot water bath. On cooling, 
the precipitate was collected washed with cold EtOH to give 




Yield 58.6 %; m.p. 154–157 °C; 1H NMR (DMSO): δ = 1.30 
(3H, t, CH3), 4.41 (2H, q, CH2), 6.79 (1H, d, J = 1.6 Hz, H-4’), 
7.06 (1H, d, J = 1.2 Hz, H-2’,6’), 7.20 ( 1H, t, J = 7.6 Hz, H-6), 
7.46 (1H, t, J = 8 Hz, H-7), 7.58-7.61 (2H, m, H-5,8), 7.85 ( 
1H, dd, J = 8.8 Hz, J = 1.6 Hz, H-2), 8.09 (1H, s, -NH), 8.21 
(1H, d, J =7.2 Hz, H-1), 8.40 (1H, d, J =1.2 Hz, H-4), 10.69 (1H, 
s, -CH=N). 13C NMR: δ = 13.7, 37.0, 109.3, 109.4, 109.8, 
116.6, 118.9, 119.0, 120.6, 122.1, 122.3, 123.8, 125.9, 
126.0, 134.6, 139.9, 140.9, 147.8. ESI-MS: m / z = 383[M+1] 
(100 %), 385 [M+1+2] (65 %), 387 [M+1+4] (37%). Found, %: 
C 64.47; H 4.58; N 10.73. C21H17N3Cl2. 0.5 H2O Calcd, %: C 




Yield 83.1 %; m.p.112–116 °C; 1H NMR (DMSO): δ = 1.31 
(3H, t, CH3), 4.44 (2H, q, CH2), 6.46-6.51 (1H, m, H-6’), 7.11–
7.22 (2H, m, H-6, 3’), 7.29-7.34 (1H, m, H-4’), 7.45 (1H, td, J 
= 8 Hz, J = 1.2 Hz, H-7), 7.59-7.63 (2H, m, H-5,8), 7.84 (1H, 
dd, J = 8.4 Hz, J = 1.6 Hz, H-2), 8.25 (1H, d, J = 7.2 Hz, H-1), 
8.32 (1H, s, -NH), 8.41 (1H, d, J = 1.2 Hz, H-4), 10.32 (1H, s, 
-CH=N). ESI-MS: m / z = 350 [M+1] (100 %). Found, %: C 
71.85; H 5.32; N 11.54. C21H17N3F2. 0.2 H2O Calcd, %: C 




Yield 66.5 %; m.p. 148–151 °C; 1H NMR (DMSO): δ = 1.30 
(3H, t, CH3), 4.43 (2H, q, CH2), 6.40-6.46 (1H, m, H-4’), 6.71 
(2H, dd, J = 10.4 Hz, J = 2.4 Hz, H-2’,6’), 7.20 (1H, t, J =  
7.6 Hz, H-6), 7.45 (1H, td, J = 7.2 Hz, J = 1.2 Hz, H-7), 7.58-
7.62 (2H, m, H-5,8), 7.85 (1H, dd, J = 8.4 Hz, J = 1.6 Hz, H-2), 
8.07 (1H, s, -NH), 8.22 (1H, d, J = 7.6 Hz, H-1), 8.42 (1H, d, J 
= 1.2 Hz, H-4), 10.63 (1H, s, -CH=N). 13C NMR: δ = 13.7, 37.0, 
92.2, 92.5, 92.8, (94.3, 94.6), (109.2, 109.3), (118.9, 119.0), 
120.6, (122.1, 122.3), 123.9, (125.9, 126.1), (139.8, 139.9), 
140.4, 148.1, 148.3, 148.4, (162.2, 162.3), (164.5, 164.7). 
ESI-MS: m / z = 350 [M+1] (100 %). Found, %: C 71.39; H 





Yield 78.7 %; m.p.141–144 °C; 1H NMR (DMSO): δ = 1.32 
(3H, t, CH3), 3.70 (3H, s, OCH3), 4.43 (2H, q, CH2), 6.86 (2H, 
d, J = 8.8 Hz, H-2’,6’), 7.07 (2H, d, J = 8.8 Hz, H-3’,5’), 7.22 
(1H, t, J = 7.6 Hz, H-6), 7.46 (1H, t, J = 7.2 Hz, H-7), 7.59-7.62 
(2H, m, H-5,8), 7.83(1H, dd, J = 8.4 Hz, J = 1.6 Hz, H-2), 8.02 
(1H, s, -NH), 8.22 (1H, d, J = 7.6 Hz, H-1), 8.34 (1H, d, J =  
1.2 Hz, H-4), 9.99 (1H, s, -CH=N). 13C NMR: δ = 13.7, 36.9, 
55.2, 109.2, 109.3, 112.8, 114.5, 117.9, 118.8, 120.4, 122.1, 
122.3, 123.3, 125.8, 127.2, 136.9, 139.3, 139.8, 139.9, 
152.2. ESI-MS: m / z = 344 [M+1] (100 %). Found, %: C 75.45; 
H 6.61; N 11.22. C22H21N3O. 0.25 H2O. 0.25 C2H6O Calcd, %: 




Yield 44.6 %; m.p. 98–102 °C; 1H NMR (DMSO): δ = 1.30 (3H, 
t, CH3), 2.18 (3H,s, CH3(phenyl)), 2.19 (3H,s, CH3(phenyl)), 4.42 
(2H, q, CH2), 6.85 (1H, s, H-3’), 6.92 (1H, d, J = 8Hz, H-5’), 
7.20 (1H, t, J = 7.6 Hz, H-6), 7.39 (1H, d, J = 8Hz, H-6’), 7.46 
(1H, td, J = 8.4 Hz, J = 1.2 Hz, H-7), 7.57-7.61 (2H, m, H-5,8), 
7.83 (1H, dd, J = 8.8Hz, J = 1.2 Hz, H-2), 8.22 (1H, d, J = 7.6 
Hz, H-1), 8.27 (1H, s, -NH), 8.33 (1H, d, J = 1.6 Hz, H-4), 9.27 
(1H, s, -CH=N). 13C NMR: δ = 13.7, 17.4, 20.1, 36.9, 109.2, 
109.3, 112.1, 118.1, 118.9, 120.4, 120.5, 122.1, 122.3, 
123.5, 125.8, 126.6, 127.0, 127.1, 130.8, 138.9, 139.4, 
139.8, 141.3. ESI-MS: m / z = 342 [M+1] (100 %). Found, %: 
C 78.18; H 6.91; N 9.27. C23H23N3. 0.5 H2O.0.25 C2H6O 




Yield 65.1 %; m.p. 152–156 °C; 1H NMR (DMSO): δ = 1.30 
(3H, t, CH3), 2.12 (3H,s, CH3(phenyl)), 2.19 (3H,s, CH3(phenyl)), 
4.42 (2H, q, CH2), 6.83 (1H, dd, J = 8.4 Hz, J = 2.4 Hz, H-6’), 
6.91 (1H, d, J = 2Hz, H-2’), 6.96 (1H, d, J = 8.4 Hz, H-5’), 7.19 
(1H, t, J = 7.2 Hz, H-6), 7.43 (1H, td, J = 8.4 Hz, J = 1.2 Hz, H-
7), 7.58 (2H, dd, J = 8.8 Hz, J = 2.4 Hz, H-5,8), 7.82 (1H, dd, J 
= 8.8Hz, J = 1.2 Hz, H-2), 7.99 (1H, s, -NH), 8.20 (1H, d, J = 
7.6 Hz, H-1), 8.32 (1H, d, J =1.6 Hz, H-4), 9.97 (1H, s, -CH=N). 
13C NMR: δ = 13.7, 18.5, 19.7, 36.9, 109.2, 109.3, 113.1, 
118.0, 118.9, 120.5, 122.1, 122.3, 123.4, 125.4, 125.8, 
127.1, 129.9, 136.5, 137.1, 139.3, 139.8, 143.7. ESI-MS: m / z = 
342 [M+1] (100 %). Found, %: C 80.08; H 7.12; N 12.02. 
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Yield 86.9 %; m.p. 195–199 °C; 1H NMR (DMSO): δ = 1.30 
(3H, t, CH3), 2.12 (3H, s, CH3(phenyl)), 2.19 (3H,s, CH3(phenyl)), 
4.42 (2H, q, CH2), 7.17–7.23 (3H, m, H-6,2’,6’), 7.45 (1H, td, 
J = 8.4 Hz, J = 1.2 Hz, H-7), 7.59-7.63 (4H, m, H-5,8,3’,5’), 
7.87 (1H, dd, J = 8.8Hz, J = 1.6 Hz, H-2), 8.15 (1H, s, -NH), 
8.21 (1H, d, J = 7.6 Hz, H-1), 8.42 (1H, d, J =1.2 Hz, H-4), 
10.89 (1H, s, -CH=N). 13C NMR: δ = 13.7, 37.0, 98.4, 109.3, 
109.4, 111.8, 119.1, 120.2, 120.5, 122.1, 122.3, 123.9, 
125.9, 126.0, 133.5, 139.8, 139.9, 141.5, 148.8. ESI-MS: m / 
z = 339 [M+1] (100 %). Found, %: C 77.02; H 5.65; N 16.29. 




CELL CULTURE AND REAGENTS 
CHO-K1 cells were purchased from ATCC and maintained at 
37 °C in 5 % CO2 atmosphere. Dulbecco’s modified Eagle’s 
medium (DMEM) / F12 (Sigma, St. Louis, MO) (1 : 1) nutrient 
mixture medium supplemented with 10 % foetal bovine 
serum, 1 % of a 100 U / mL penicillin-streptomycin solution, 
2 mM L-glutamine and 1 mM sodium pyruvate was used in 
all cell incubations. Hyclone characterized fetal bovine se-
rum (FBS) was purchased from Thermo Scientific. 2′,7′-
Dichlorofluorescin diacetate (DCFH-DA), 2,2-diphenyl-1-
picrylhydrazyl (DPPH), 7-ethoxyresorufin, sodium pyruvate 
and L-glutamine were obtained from Sigma (St. Louis, MO). 
3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium 
bromide (MTT) was purchased from Invitrogen (Oregon, 
USA). Phenobarbital-induced rat liver microsomes were 
kindly provided by Prof. Hilmi Orhan. Test materials were 
dissolved in dimethyl sulfoxide (DMSO) and the final 
concentration of DMSO never exceeded 0.1 % v / v in cell 
culture medium. 
 PC12 cells were a generous gift from Professor Lloyd 
A. Greene (Department of Pathology and Cell Biology, 
Columbia University, New York, USA). They were maintained 
in RPMI 1640 supplemented with 10 % horse serum, 5 % fetal 
bovine serum, 100 U / mL penicillin G and 100 µg mL–1 
streptomycin. The cells were cultured on plates coated with 
collagen obtained from rat tail and were grown at 37 °C in 
humidified air containing 5 % CO2. Two-thirds of the 
growing medium was changed every 2–3 days. 
 
CYTOTOXIC EFFECTS VIA THE MTT ASSAY 
CHO-K1 cells were seeded in 96-well plates (5 × 103 cells / 
well) and incubated at 37 ˚C in a humid atmosphere 
containing 5 % CO2 for 24 h. Cells were treated with the 
newly synthesized compounds (10 µM) for 24 h. Control 
(medium only), vehicle control and positive control (15 µM 
Triton X-100) were included in every experiment. Following 
the exposure period, the medium was removed, cells were 
washed with phosphate buffered saline (PBS) and then 
incubated with MTT (1 mg mL–1) for 4 h at 37 °C. MTT solu-
tion was removed and formazan crystals were dissolved in 
DMSO. The absorbance was recorded at 550 nm on a 
microplate reader. The ratio of the absorbance of treated 
samples to the absorbance of control (taken as 100 %) was 
expressed as % cell viability. 
 
ANTIOXIDANT ACTIVITY ON ROS-INDUCED DCFH-DA 
OXIDATION 
For estimation of intracellular ROS, DCFH-DA was used as a 
probe. In cellular systems the non-fluorescent probe DCFH-
DA readily crosses the cell membrane and undergoes hy-
drolysis by intracellular esterases to non-fluorescent 2',7'-
dichlorofluorescin (DCFH). In the presence of ROS, DCFH is 
oxidized to highly fluorescent dichlorofluorescein (DCF) [25] 
which can be detected by a fluorescent microplate reader.  
 Cells were seeded in black 96-well plates at a density 
of 5 × 103 cells / well and incubated at 37 ˚C in a humid at-
mosphere containing 5 % CO2 for 24 h for cell attachment. 
The medium was removed and then cells were incubated 
with DCFH-DA (20μM) containing medium for 30 minutes. 
Cells were washed with PBS to remove excess DCFH-DA.  
10 µM synthesized compounds and 10 µM cumene 
hydroperoxide (CMHP) were added into medium. The 
production of fluorescent DCF was evaluated by monitoring 
fluorescence intensity at 488 nm excitation, 530 nm 
emission wavelengths for 60 minutes. 
 
DPPH FREE RADICAL SCAVENGING ACTIVITY 
Free radical scavenging activity of newly synthesized 
compounds was tested by their ability to bleach the stable 
radical DPPH.[26] DPPH presents a maximum of absorbance 
at 515 nm; when DPPH reacts with an antioxidant 
compound, which can donate hydrogen, this absorbance 
diminishes and can be measured on a visible 
spectrophotometer. 20 μL of the samples (100 μM) were 
added to 180 μL of DPPH solution (150 μM) in methanol–
water (80 : 20, v / v) in 96-well plates, incubated for 30 
minutes at room temperature then DPPH reduction was 
estimated at 517 nm. Percentage inhibition by the sample 
treatment was determined by comparison with a DMSO-
treated control group. All experiments were carried out in 
triplicate. MLT and butylated hydroxytoluene (BHT) were 
used as a reference compounds. The radical scavenging 
activities were expressed as the percent of inhibition and 
were calculated by using the below formula: 
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where A0 is the absorbance of the control (blank) and A1 is 
the absorbance of the test compound. 
 
INHIBITION OF NEUROTOXICITY INDUCED BY Aβ IN PC12 
CELLS 
Cell viability after exposure to Aβ25–35 was determined by 
MTT assay, which was performed as previously described 
with some modifications. [27] Briefly, the cells were seeded 
in collagen-coated 96-well plates at a density of 5 × 104 cells 
/ well and were allowed to adhere at 37 °C for 48 h. Three 
different concentrations of carbazole derivatives (5, 25 and 
100 µM) were added in duplicate and incubated for 3 h. 
Maximum concentration of DMSO in the wells was kept 
below 0.5 %. Aβ25–35 was then added at a final concentra-
tion of 5 µM for an additional 24 h in the presence or 
absence of test compounds. After 24 h, the medium was 
replaced with 20 µL of MTT 0.5 mg mL–1 dissolved in RPMI 
and incubated for an additional 2 h at 37 °C. Afterwards, 
formazan crystals were solubilized in 200 µl DMSO. The 
optical density was measured at 570 nm with background 
correction at 655 nm using a Bio-Rad microplate reader 
(Model 680, Bio-Rad). Each experiment was repeated 3–5 
times. The percent inhibition of cell damage was calculated 
with reference to the absorbance of control wells not 
treated with Aβ (assumed as 100 % protection) and the 
absorbance of wells treated with Aβ in the absence of any 
test compound (assumed as 0 % protection). 
Statistical Analysis 
Unpaired Student t-test was performed to evaluate the 
significance of the differences between groups. Differences 
with p < 0.05 were considered as statistically significant. 
 
RESULTS AND DISCUSSION 
Chemistry 
Synthesis of all described carbazole hydrazone derivatives 
were carried out according to the method described in lit-
erature[24] (Scheme 1). 9-Ethyl-9H-carbazole-3-carboxalde-
hyde was heated with several phenyl hydrazine derivatives 
in the presence of ethanol to obtain carbazole hydrazone 
derivatives. 
Cytotoxic Effects of the Synthesized 
Compounds 
The failure of early identification of toxic effects of com-
pounds resulted in attrition of new drug candidates,[19] 
which cause important losses for pharmaceutical industry. 
Therefore, screening for cytotoxicity has become one of the 
most important steps in early phases of drug discovery. In 
the present study cytotoxicity of the synthesized carbazole-
hydrazone derivatives were evaluated in CHO-K1 cells by 
using a tetrozolium salt, MTT. The assay based on the re-
duction of MTT only by metabolically active cells to a col-
ored formazan product that can be quantified 
spectrophotometrically.[20] Almost all compounds (10 µM) 
were found to have no cytotoxic effect more than melato-
nin (MLT), an endogenous indole compound with known 
antioxidant and anticarcinogenic activity (Figure 2) on CHO-
K1 cells when incubated for 24 hours. Only 3e and 3k 
decreased cell viability more than MLT. Among halogen-
ated carbazole derivatives chloro- and fluoro-substituted 
ones were found to be more cytotoxic than bromo-substi-
tuted compounds. The substances without any halogen 
group and with methoxy substitution on aromatic ring 3p, 
3q, 3r, did not have any effects on cell viability (Figure 3). 
Antioxidant Effects of the Synthesized 
Compounds 
The protective effect of synthesized carbazole-hydrazone 
derivatives (10 µM) against cumene hydroperoxide induced 
DCFH-DA oxidation was determined in CHO-K1 cells that 
were preloaded with the fluorescent probe. Oxidation of 
the probe located in the cytosol was detected after 60 min 
of incubation (Figure 4). All of the carbazole derivatives, 
except 3b, 3c, 3g and 3j had potent reducing activity against 
DCFH oxidation, even higher than MLT. Compounds 3o, 3p, 
3q and 3r bearing no halogen substituent, were found to 
have reducing activity where 3r was found to be the most 
potent antioxidant among all tested compounds. Among 
the halogenated derivatives fluoro-substituted ones were 
found to have better antioxidant effects compared to 
chloro- and bromo-halogenated derivatives. 
 Free radical scavenging activity of the newly 
synthesized compounds was further investigated in a cell 
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The radical scavenging activity of the compounds was 
detected via decrease in the absorbance of DPPH. All of the 
synthesized compounds had radical scavenging activity in 
tested concentration (100 µM) where MLT was found to 
have the lowest effect (Figure 5). Among mono-halogen-
ated derivatives m-substituted derivatives were found to 
have higher activity and p-halogenation was found to 
decrease antioxidant activity which was similar to our 
previous findings.[21,22] 3r was found to be the most potent 
radical scavenger among all tested compounds similar to its 
reducing effect found in DCFH assay (Figure 4). 
 Antioxidant molecules have proved to be effective in 
AD mouse models and small clinical studies. Clinical trials 
for AD prevention and treatment by antioxidants are still 
under discussion. Hence, advance studies are necessary to 
determine if antioxidants may decrease the risk or slow the 
progression of the disease for AD patients.[23] 
Protection of Neuronal PC12 Cells 
Against Aβ-Induced Damage 
Neuroprotective capacity of synthesized derivatives was 
assessed in PC12 neuronal cells challenged with Aβ, which 
is a well-established cell model of neurodegeneration. 
None of the compounds showed any cytotoxicity against 
the cells when incubated with the cells alone (data not 
shown). Several carbazole derivatives showed significant 
protection against Aβ at 25 and 100 µM including 3d, 3e, 
3h and 3n. It was remarkable to note that compound 3r 
showed a high protection against Aβ damage at the lower 
dose of 25 µM (Figure 6). 
 
Figure 4. DCFH oxidation in CHO cells after 60 minutes 
incubation with compounds (10 µM) in the presence of 
cumene hydroperoxide (CMHP). Bars represent ‘medium ± 
standard deviation’ values obtained from five individual 
experiments. Statistical comparisons of samples with CMHP 
were compared to CMHP alone control group. *p < 0.05,  
** p < 0.005.(MLT: Melatonin). 
 
Figure 5. Radical scavenging activity of compounds  
(100 µM) determined by DPPH assay. Bars represent 
‘medium ± standard deviation’ values from four different 
experiments. BHT and MLT were used as reference (BHT: 
Butylated hydroxytoluene, MLT: Melatonin). 
 
Figure 6. Protection of PC12 neuronal cells against Aβ-
induced damage by synthesized carbazole derivatives 
measured by MTT assay. PC12 cells seeded in collagen-
coated 96-well microplates were pre-incubated with 
different concentrations of synthesized derivatives for 3 h 
and then challenged with Aβ 5 µM. MTT assay was 
performed to measure cell viability after 24 h. Each 
experiment was repeated 3–5 times. Concentrations of 
analogues are expressed as µM. Data are expressed as 
mean ± S.E.M. *Significantly different from control wells 
treated with Aβ (p < 0.05). 
 
Figure 3. Effect of samples (10µM) on cell viability evaluated 
by MTT assay. Bars represent ‘medium ± standard deviation’ 
values from five individual experiments. *p < 0.05,  
** p < 0.005, *** p < 0.0005, groups compared to vehicle 
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 Compounds with electron withdrawing moieties on 
the phenyl ring including those bearing Cl (3–3f), Br (3–3i) 
and F (3–3n) showed much better protective effects in 
PC12 cells compared to derivatives bearing electron 
donating groups including the ones containing methoxy 
(3o) and methyl moieties (3p–3q) on the phenyl ring. 
Among halogen containing synthesized compounds, the 
ones bearing two halogen groups on the phenyl ring, 
including 3d and 3e with 3,4-dichlorophenyl and 3,5-
dichlorophenyl rings, respectively, as well as 3m and 3n, 
with 2,5-dibromophenyl and 3,5-dibromophenyl rings, 
respectively, were more effective than those bearing only 
one halogen group. 
 
CONCLUSION 
A series of carbazole-hydrazone derivatives was 
synthesized and evaluated for their cytotoxicity, 
antioxidant potential and protective effect against amyloid 
β-induced damage in neuronal PC12 cells. The results 
pointed out that almost all compounds were found to have 
no cytotoxic effect more than the known antioxidant, 
melatonin (MLT).  
 Most of the carbazole derivatives were found to 
have reducing potential against DCFH oxidation even 
higher than MLT. This higher reducing potential may be 
related with halogen- substituted aromatic moiety. 
Compounds bearing halogen substituents were found to 
have higher activities, especially fluoro-substituted 
compounds that had the highest reducing potential.  
 The synthesized novel compounds also exhibited 
good DPPH radical scavenging activity. Particularly m-
substituted derivatives were found to have higher activity 
than rest of the compounds. The most significant 
compound was 3r regarding the antioxidant activity tests. 
Furthermore, compound 3r showed a high protection 
against Aβ damage at the lower dose of 25 µM. Correlation 
between the activities of 3r as antioxidant and Aβ damage 
protection is promising for further development of 
carbazole-hydrazone derivatives as future AD drug.  
 Antioxidant molecules have proved to be effective in 
AD mouse models and small clinical studies. Clinical trials 
for AD prevention and treatment by antioxidants are still 
under discussion. Hence, advance studies are necessary to 
determine if antioxidants may decrease the risk or slow the 
progression of the disease for AD patients.[23]  
 These preliminary results are promising and we are 
confident that the N-alkyl carbazole derivatives may 
represent new leads in the search for novel AD therapy. 
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